Match each inpatient clinical scenario with the most appropriate targeted pharmacologic intervention based on current clinical guidelines.
- A 68-year-old man develops ventilator-associated pneumonia on hospital day 8. Sputum cultures are pending, but he has a known history of colonization with extended-spectrum beta-lactamase (ESBL)-producing Klebsiella pneumoniae.Initiate intravenous meropenem
- A 54-year-old woman with acute myeloid leukemia has profound neutropenia and persistent fever despite broad-spectrum antibacterial therapy for 5 days. Chest computed tomography reveals a pulmonary macronodule surrounded by a ground-glass perimeter.Initiate intravenous voriconazole
- A 75-year-old woman presents with severe lower abdominal pain, a leukocyte count of 32,000/mm³, and copious watery diarrhea two weeks after completing a course of levofloxacin for an upper respiratory infection.Initiate oral fidaxomicin
- A 42-year-old man is admitted with acute-onset high fever and a new holosystolic murmur. Blood cultures rapidly grow methicillin-resistant Staphylococcus aureus (MRSA) with a vancomycin minimum inhibitory concentration (MIC) of 4.0 mcg/mL.Initiate intravenous daptomycin
Answer
ESBL pneumonia is treated with meropenem; invasive pulmonary aspergillosis presenting with a halo sign requires voriconazole; severe C. difficile infection mandates oral fidaxomicin; and high-MIC MRSA endocarditis requires switching to daptomycin.
Each clinical scenario requires a critical deviation from standard empiric broad-spectrum therapy based on diagnostic clues: carbapenems for confirmed ESBL exposure, voriconazole for the characteristic fungal 'halo sign', fidaxomicin for severe toxin-mediated colitis, and daptomycin for highly resistant MRSA bacteremia.
Step-by-Step Solution
Key Concept
Targeted antimicrobial therapy for severe, resistant, and opportunistic nosocomial infections